Tags:BioTechBodyBuildingDevelopmentEngineeringInformationITManufacturingPlatformWebsite
Nkarta is a clinical-stage biotechnology company advancing the development of allogeneic natural killer (NK) cell therapies for cancer. By combining its cell expansion and cryopreservation platform with proprietary cell engineering technologies, Nkarta is building a pipeline of cell therapy candidates generated by efficient manufacturing processes, and engineered to enhance tumor targeting and improve persistence for sustained activity in the body. For more information, please visit the company’s website at www.nkartatx.com.
Location: United States, California, South San Francisco
Member count: 51-200
Total raised: $114M
Founded date: 2015

Investors 5

Funding Rounds 1

DateSeriesAmountInvestorsDeal News
06.09.2019Series B$114M-fiercebiot...

Mentions in press and media 8

DateTitleDescriptionCategoryAuthorSource
11.09.2019Biopharmac...Biopharmaceutical company Nkar...--pulse2.com...
06.09.2019Nkarta The...Nkarta Therapeutics, a South S...USA-finsmes.co...
05.09.2019Nkarta The... SOUTH SAN FRANCISCO, CA, Nka...--vcnewsdail...
04.09.2019Nkarta net...Amgen Ventures and Deerfield M...Biotech-fiercebiot...
04.09.2019Nkarta net...Amgen Ventures and Deerfield M...Biotech-fiercebiot...
30.07.2019Pharma lea...When I was 13 years old, my do...--statnews.c...
14.12.2018Shinichi T...→ Jeff Abbey is jump­ing to th...-Amber Tongendpts.com...
-Nkarta’s n...The first cell therapies for c...--medcitynew...